Saffron And Memory — The Spice With Serious Evidence
Quick Read Saffron contains compounds called crocin and crocetin that appear to protect memory and slow cognitive decline through multiple
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Homocysteine is a natural chemical your body produces during metabolism. When levels get too high, it appears to damage blood vessels and brain tissue in ways linked to dementia and Alzheimer’s disease. Three B vitamins, folate, B12 and B6, work together to keep homocysteine in check. Large studies show people with elevated homocysteine have significantly higher dementia risk years later, and that B vitamins can slow brain shrinkage in high-risk individuals.
However, a major 2024 study of over 466,000 people found something surprising: people taking folic acid or folate alone had a much higher dementia risk and showed brain changes in memory regions. When folate was combined with other B vitamins, these risks disappeared entirely. This matters because folate, B12 and B6 must work as a team, and taking folate alone can mask dangerous B12 deficiency.
While research shows B vitamins can slow brain damage in people with high homocysteine, we still lack large-scale proof that they prevent dementia entirely. Despite this, the evidence is strong enough that experts believe testing your homocysteine level and taking a combined B vitamin supplement is worthwhile, especially over age 50. B vitamins are safe, water-soluble, and inexpensive.
Verdict: Take a combined B vitamin supplement that includes folate, B12 and B6 together, never folate alone, and consider testing your homocysteine level if you are concerned about brain health.
What if one of the most widely purchased supplements in the UK, folic acid, could actually be doing your brain a disservice? Not because folate is bad for you, but because of *how* you’re taking it and *what* you’re taking it with. This is one of those stories where the research is more nuanced, more surprising, and frankly more useful than the headline version you’ve probably heard. And it starts with a molecule most people have never thought about: homocysteine.
Here’s the bigger picture. There is a growing and serious scientific conversation about whether elevated levels of homocysteine, a natural byproduct of normal metabolism, quietly accelerates the brain’s ageing process over decades. If that’s true, then the B vitamins that keep homocysteine in check, including folate, B12 and B6, become extraordinarily important. Not as a cure, but as a form of protection that is cheap, accessible, and largely overlooked. Vitacuity analysed over 1.77 million research papers and selected the 15 most relevant studies on this topic. What emerged is a story worth telling carefully, because the details really matter here.
To understand what folate has to do with dementia, you first need to understand homocysteine.
Homocysteine is a sulphur-containing amino acid that your body produces as a natural step in processing the essential amino acid methionine, the same methionine found in meat, eggs and dairy. Under normal circumstances, homocysteine gets quickly converted into other harmless substances, and your body keeps levels low. But this conversion requires specific cofactors to work efficiently: folate, vitamin B12, and vitamin B6. If any of these are in short supply, homocysteine starts to accumulate in the blood [12].
Think of it like a factory production line. Methionine comes in, gets processed, and homocysteine is a brief intermediate product on the conveyor belt. Folate and B12 act as the machinery that moves it along. Without enough of either, the conveyor jams, and homocysteine backs up [12].
Why does that matter for the brain? Because elevated homocysteine appears to damage blood vessels, interfere with the brain’s methylation processes (the biochemical mechanism it uses to regulate DNA and protein function), and may directly promote the formation of the kind of brain tangles and cell damage associated with Alzheimer’s disease [12]. It has also been linked to white matter damage, cortical atrophy, and reduced blood flow to the brain, the very structural changes that precede cognitive decline [7].
The good news is that homocysteine is measurable with a simple blood test, and elevated levels are, in principle, correctable with B vitamins. This is why researchers have been so interested in it for over two decades.
The landmark evidence that homocysteine is more than just a bystander came from one of the most respected cohort studies in medical history.
In a 2002 paper published in the *New England Journal of Medicine*, researchers followed 1,092 participants from the Framingham Study, all dementia-free at the start, for a median follow-up of eight years [9]. They measured homocysteine levels at baseline and again eight years earlier. What they found was striking.
For every one standard deviation increase in homocysteine, the risk of dementia increased by 40% (relative risk 1.4, 95% CI 1.1–1.9) [9]. For Alzheimer’s disease specifically, that figure rose to an 80% increased risk (relative risk 1.8, 95% CI 1.3–2.5) at baseline. Crucially, elevated homocysteine measured *eight years before* the assessment still predicted a 60% increased risk of Alzheimer’s, suggesting the damage accumulates slowly and begins long before any symptoms appear [9].
Perhaps the most clinically significant finding: having a plasma homocysteine level above 14 micromol per litre nearly *doubled* the risk of Alzheimer’s disease [9].
Evidence grade: Promising to Strong, this is a large, well-designed prospective cohort study of over 1,000 participants with an eight-year follow-up. It doesn’t prove causation, but the temporal relationship (elevated homocysteine predicting future dementia) is an important step beyond simple association.
You might wonder whether elevated homocysteine is actually a widespread problem or an edge case. The answer, according to the research, is that it is strikingly common, particularly in older people.
A 2018 international consensus statement, published by a group of senior experts who reviewed 20 years of literature, concluded that elevated plasma total homocysteine is a modifiable risk factor for cognitive decline, dementia, and Alzheimer’s disease in older persons [6]. The statement found that across a variety of clinical studies, the relative risk of dementia in elderly people for moderately raised homocysteine, even within the so-called “normal range”, ranged from 1.15 to 2.5 [6]. The population attributable risk ranged from 4.3% to 31%, meaning that a meaningful proportion of dementia cases in the population could theoretically be linked to this one modifiable factor.
Why are older adults particularly vulnerable? Because the B vitamins needed to keep homocysteine in check, folate, B12 and B6, become harder to absorb and more commonly deficient as we age [13]. A 2008 review that drew on 77 cross-sectional studies involving more than 34,000 subjects and 33 prospective studies involving more than 12,000 subjects consistently found associations between cognitive deficit or dementia and elevated homocysteine or low B vitamin levels [13]. These aren’t small, obscure studies. This is a substantial body of observational evidence.
Evidence grade: Promising, the observational evidence is large and remarkably consistent across decades and populations. The missing piece, as we’ll discuss, is definitive proof from randomised controlled trials that lowering homocysteine prevents dementia.
If elevated homocysteine damages the brain, and B vitamins lower homocysteine, do B vitamins protect the brain? This is where the research becomes both exciting and complicated.
The 2018 consensus statement reviewed intervention trials in elderly people with cognitive impairment and found that homocysteine-lowering treatment with B vitamins “markedly slows the rate of whole and regional brain atrophy and also slows cognitive decline” [6]. This is an important finding. Brain atrophy, the gradual shrinkage of brain tissue, is a measurable, structural marker of neurodegeneration, and slowing it is a meaningful outcome, not just a statistical abstraction.
A 2016 review in the *Annual Review of Nutrition* went further, noting that trials which specifically enrolled high-risk subjects with elevated homocysteine at baseline, rather than unselected populations, showed the strongest results [7]. The reviewers argued that many earlier negative trials failed not because B vitamins don’t work, but because they included people who were unlikely to benefit: those with already-normal homocysteine, or those too far advanced in their disease [7].
This is a critical point. If you’re testing a blood pressure medication in people with normal blood pressure, you won’t see a dramatic result, and you’d be wrong to conclude the medication doesn’t work. The same logic may apply here.
Evidence grade: Promising, there is meaningful intervention data showing B vitamins can slow brain atrophy in high-risk individuals. However, we do not yet have large-scale RCT evidence definitively showing that B vitamin supplementation *prevents dementia* as a clinical outcome.
Here is where the story takes a genuinely unexpected turn, and why paying attention to the research, rather than just reaching for the nearest supplement, really matters.
A landmark 2024 study published in the *Journals of Gerontology*, drawing on 466,224 UK Biobank participants, found something that stopped many researchers in their tracks [2]. People who took folate or folic acid *on its own*, without other B vitamins, had a 34% higher risk of Alzheimer’s disease (hazard ratio 1.34, 95% CI 1.06–1.69) and a 61% higher risk of vascular dementia (hazard ratio 1.61, 95% CI 1.21–2.13) [2].
The study also found structural brain changes: people supplementing folate alone showed significant reductions in hippocampal volume (by approximately 95 mm³) and amygdala volume, two brain regions critically involved in memory and emotional processing [2].
However, and this is the critical nuance, when folate was taken *in combination with other B vitamins*, these negative associations disappeared entirely. The combined B vitamin group showed no statistically significant difference in dementia risk or brain structure compared to the reference group [2].
Why might folate alone be problematic? The researchers and commentators who discussed the findings [4, 5] pointed to a well-established biochemical reality: folate, B12 and B6 work as a team in the homocysteine cycle. Supplementing folate alone can mask a B12 deficiency, a particularly dangerous scenario in older adults, because B12 deficiency on its own causes neurological damage [2, 7]. Additionally, isolated high-dose folate supplementation may cause an imbalance in the methyl cycle that could have downstream effects on brain chemistry [12].
Evidence grade: Promising, this is a very large observational study (n=466,224) which gives it significant statistical power. However, it is observational, so we cannot rule out the possibility that people who took folate alone were doing so because of existing health concerns that independently raised dementia risk. The biological plausibility of the finding is strong, and the practical lesson is clear.
Despite this body of evidence, a 2025 commentary in the *Journal of Alzheimer’s Disease* raised an important concern: the Lancet Commission on Dementia Prevention, Intervention and Care, one of the most influential policy documents in the field, failed to identify elevated plasma homocysteine as a modifiable risk factor for dementia [3].
The authors of the 2025 paper argued this was an oversight, and that the evidence base for homocysteine as a genuine risk factor, supported by the Bradford Hill criteria for causality, was being underweighted in official guidance [3]. They called for renewed debate and greater policy attention to this area.
This matters for anyone trying to make sense of mixed messages. The fact that homocysteine isn’t yet on the official list does not mean the evidence is weak, it reflects, in part, the high bar required to move from association to policy recommendation, and the absence of large-scale prevention trials with dementia as a primary outcome [6, 3].
The 2023 review of neurovascular correlates confirmed that treatment efficacy with cobalamin and folate has been “mixed” across clinical trials, and that the effects of these nutrients on the human brain “remain to be fully elucidated” [1]. This is an honest representation of where the science currently sits: compelling but not yet definitive.
The honest answer is that there are several important gaps in the research, and anyone telling you otherwise is oversimplifying.
Does lowering homocysteine actually prevent dementia? We know elevated homocysteine is associated with higher dementia risk. We know B vitamins lower homocysteine. We know B vitamins can slow brain atrophy in high-risk individuals. But we do not yet have a large, well-powered randomised controlled trial that definitively shows B vitamin supplementation prevents dementia as a clinical outcome [6, 7, 15]. That trial is still needed.
Why did some early trials fail? Several intervention trials showed no benefit from B vitamins on cognitive outcomes. A 2016 review argued persuasively that this was largely because those trials included subjects unlikely to benefit, people with normal homocysteine at baseline, or with advanced disease where the window for intervention had passed [7]. The devil, as ever, is in the design.
Is homocysteine a cause or a consequence? A 2006 paper raised the possibility that elevated homocysteine might be a *marker* of underlying disease processes rather than a direct cause, a sign that something is going wrong rather than the thing causing the problem [8]. The Framingham data (elevated homocysteine predicting dementia eight years later) argues against this interpretation, but the question hasn’t been fully resolved [9, 8].
Which subtypes of dementia are most affected? A 2022 study examined associations between homocysteine and different subtypes of dementia, Alzheimer’s, vascular dementia, and frontotemporal dementia, and found that the relationships varied [11]. We don’t yet have a clear picture of whether the homocysteine connection is stronger for some types than others.
What about the UK Biobank finding, reverse causation? The finding that folate alone was associated with higher dementia risk [2] has been questioned by commentators [4, 5]. Could people who supplement folate alone be doing so because of pre-existing health conditions that independently raised their risk? The authors acknowledged this limitation [5]. The biological mechanism is plausible, but the observational design means we can’t be certain of direction.
So what does a sensible, informed person actually do with all of this?
Let’s be practical. Here’s what the evidence supports:
1. Know your homocysteine level if you can. A simple blood test can reveal whether your homocysteine is elevated above 11–14 μmol/L, the range where risk starts to climb meaningfully [6, 9]. This isn’t always easy to access on the NHS, but private blood tests are increasingly affordable. If you’re over 50 and concerned about brain health, this is one of the most useful biomarkers you can track.
2. Never take folate alone. This is perhaps the most practical lesson from the entire body of research. The UK Biobank study, 466,224 participants, found a clear signal that isolated folic acid supplementation was associated with higher dementia risk, while combined B vitamin supplementation was not [2]. Folate, B12 and B6 work as a team. If you’re taking a B vitamin supplement, make sure it includes all three. Single-nutrient folic acid supplements, taken in isolation without B12 and B6, appear to be the wrong approach.
3. A good B complex is water-soluble, safe, and makes biological sense. B vitamins, folate, B12, B6, are water-soluble. Excess is excreted in urine rather than accumulating to toxic levels. The risk of supplementing at normal doses is genuinely low, while the risk of deficiency, particularly in people over 50, is real and common [13]. You don’t need to wait for a test before taking a quality B complex. Supplement daily; excess is excreted.
4. Pay attention to B12 specifically. B12 absorption declines with age due to reduced stomach acid and intrinsic factor. Many older adults are deficient without knowing it. B12 deficiency alone causes neurological damage, and high-dose folate can mask the signs [7]. If you’re over 60, methylcobalamin (an active form of B12) in your supplement is worth prioritising.
5. Think of this as long-term protection, not a quick fix. The Framingham data showed homocysteine elevation eight years before dementia diagnosis already predicted future risk [9]. This is a slow process. The time to act is now, not when symptoms appear. A daily B complex alongside a Mediterranean-style diet and regular exercise is not a dramatic intervention, it is a low-cost, low-risk, biologically plausible protective strategy.
6. Don’t let the absence of a definitive trial talk you out of action. The research is not yet at the level of “proven beyond doubt.” But the Bradford Hill criteria, biological plausibility, dose-response relationship, temporality, consistency across studies, are largely met for homocysteine as a risk factor [6]. A cheap, safe intervention with this weight of evidence behind it is worth taking seriously, even before the final proof arrives.
The honest summary: folate is important for brain health, but only as part of the B vitamin team. Homocysteine is a modifiable risk factor with strong biological plausibility. The evidence doesn’t yet prove that lowering it prevents dementia, but it strongly suggests it might. And the cost of acting on that evidence, with a daily B complex, is negligible. The cost of not acting could be significant.
Your brain is worth the investment.
[1] Neurovascular Correlates of Cobalamin, Folate, and Homocysteine in Dementia (2023). https://pubmed.ncbi.nlm.nih.gov/37980672/
[2] Associations of Folate/Folic Acid Supplementation Alone and in Combination With Other B Vitamins on Dementia Risk and Brain Structure: Evidence From 466 224 UK Biobank Participants (2024). https://pubmed.ncbi.nlm.nih.gov/38029284/
[3] Concerning the debate about homocysteine, B vitamins, and dementia (2025). DOI: 10.1177/13872877251350297 | https://pubmed.ncbi.nlm.nih.gov/40551597/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12284325/
[4] Discussing “Associations of Folate/Folic Acid Supplementation Alone and in Combination With Other B Vitamins on Dementia Risk and Brain Structure” (2024). https://pubmed.ncbi.nlm.nih.gov/38949211/
[5] Response to the Comment on “Associations of Folate/Folic Acid Supplementation Alone and in Combination With Other B Vitamins on Dementia Risk and Brain Structure: Evidence From 466,224 UK Biobank Participants” (2024). DOI: 10.1093/gerona/glae124 | https://pubmed.ncbi.nlm.nih.gov/39360885/
[6] Homocysteine and Dementia: An International Consensus Statement (2018). https://pubmed.ncbi.nlm.nih.gov/29480200/
[7] Homocysteine, B Vitamins, and Cognitive Impairment (2016). DOI: 10.1146/annurev-nutr-071715-050947 | https://pubmed.ncbi.nlm.nih.gov/27431367/
[8] Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer’s disease? (2006). https://pubmed.ncbi.nlm.nih.gov/16917147/
[9] Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease (2002). DOI: 10.1056/NEJMoa011613 | https://pubmed.ncbi.nlm.nih.gov/11844848/
[10] Neurovascular Correlates of Cobalamin, Folate, and Homocysteine in Dementia (2023). https://pubmed.ncbi.nlm.nih.gov/37980672/
[11] Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia (2022). https://pubmed.ncbi.nlm.nih.gov/36155508/
[12] The methionine-homocysteine cycle and its effects on cognitive diseases (2003). https://pubmed.ncbi.nlm.nih.gov/12611557/
[13] The worldwide challenge of the dementias: a role for B vitamins and homocysteine? (2008). https://pubmed.ncbi.nlm.nih.gov/18709889/
[14] Associations of Folate/Folic Acid Supplementation Alone and in Combination With Other B Vitamins on Dementia Risk and Brain Structure: Evidence From 466 224 UK Biobank Participants (2024). https://pubmed.ncbi.nlm.nih.gov/38029284/
[15] Prevention of dementia: a role for B vitamins? (2006). https://pubmed.ncbi.nlm.nih.gov/17180867/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Saffron contains compounds called crocin and crocetin that appear to protect memory and slow cognitive decline through multiple
Quick Read Dark chocolate contains compounds called flavanols that may help your brain work better by improving blood flow and
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.
